AP9400695A0 - Anti-viral agents - Google Patents

Anti-viral agents

Info

Publication number
AP9400695A0
AP9400695A0 AP9400695A AP9400695A AP9400695A0 AP 9400695 A0 AP9400695 A0 AP 9400695A0 AP 9400695 A AP9400695 A AP 9400695A AP 9400695 A AP9400695 A AP 9400695A AP 9400695 A0 AP9400695 A0 AP 9400695A0
Authority
AP
ARIPO
Prior art keywords
viral agents
viral
agents
Prior art date
Application number
AP9400695A
Other versions
AP620A (en
Original Assignee
Radopath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radopath Ltd filed Critical Radopath Ltd
Publication of AP9400695A0 publication Critical patent/AP9400695A0/en
Application granted granted Critical
Publication of AP620A publication Critical patent/AP620A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
APAP/P/1994/000695A 1993-10-19 1994-10-19 Uses of a flavin in the treatment of ill-effects caused by viral infections. AP620A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939321558A GB9321558D0 (en) 1993-10-19 1993-10-19 Anti-viral agents

Publications (2)

Publication Number Publication Date
AP9400695A0 true AP9400695A0 (en) 1995-01-31
AP620A AP620A (en) 1997-10-14

Family

ID=10743784

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000695A AP620A (en) 1993-10-19 1994-10-19 Uses of a flavin in the treatment of ill-effects caused by viral infections.

Country Status (26)

Country Link
EP (1) EP0739208A1 (en)
JP (1) JPH09505804A (en)
CN (1) CN1140992A (en)
AP (1) AP620A (en)
AU (1) AU7943794A (en)
BG (1) BG100599A (en)
BR (1) BR9407862A (en)
CA (2) CA2123825A1 (en)
CO (1) CO4520283A1 (en)
CZ (1) CZ113796A3 (en)
EE (1) EE9600057A (en)
GB (2) GB9321558D0 (en)
HR (1) HRP940688A2 (en)
HU (1) HUT76322A (en)
IL (1) IL111338A0 (en)
JO (1) JO1866B1 (en)
MA (1) MA23356A1 (en)
MD (1) MD960168A (en)
NO (1) NO961547L (en)
OA (1) OA10579A (en)
PE (1) PE5596A1 (en)
PL (1) PL314008A1 (en)
SK (1) SK50696A3 (en)
UY (1) UY23844A1 (en)
WO (1) WO1995011028A1 (en)
ZA (1) ZA948191B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07188052A (en) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd Interferon activity-enhancing agent and antivirus activity-enhancing composition containing the enhancing agent and interferon
US5756479A (en) * 1994-12-29 1998-05-26 Research Development Foundation Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6933285B2 (en) * 2002-05-10 2005-08-23 The Ohio State University Flavin N-oxides: new anti-cancer agents and pathogen eradication agents
ITTO20020622A1 (en) 2002-07-16 2004-01-16 Dayco Europe Srl INTEGRATED PULLEY-TORSIONAL DAMPER GROUP
WO2004013142A1 (en) * 2002-08-02 2004-02-12 The Institute Of Radiation Medicine, Academy Of Miilitary Medical Sciences, People's Liberation Army A riboflavin derivative and its manufacture and uses
EP2545788A1 (en) * 2011-07-13 2013-01-16 Martin Hulliger Dietary multi-component system
JP2018131410A (en) * 2017-02-15 2018-08-23 ヒノキ新薬株式会社 Caspase-3 inhibitor and use thereof
JP2021500374A (en) * 2017-10-24 2021-01-07 ルネラ・バイオテック・インコーポレーテッド Mitoflavostin eliminates cancer stem cells (CSCS) by targeting flavin-containing enzymes blocking mitochondrial respiration
US20220257550A1 (en) * 2019-07-09 2022-08-18 Dsm Ip Assets B.V. Reducing the viral activity of elafibranor with riboflavin or dha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219545A (en) * 1979-03-23 1980-08-26 Collins Calvin E Treatment of infectious keratoconjunctivitis in animals
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
WO1991002529A2 (en) * 1989-08-14 1991-03-07 John Bennett Kizer Product and method for killing abnormal vertebrate cells
JP2727471B2 (en) * 1989-09-14 1998-03-11 三井農林株式会社 Influenza virus infection prevention agent
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5217716A (en) * 1990-07-18 1993-06-08 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
FR2674753B1 (en) * 1991-04-02 1995-03-10 Jean Berque NEW THERAPEUTIC INDICATIONS, PARTICULARLY FOR THE TREATMENT OF AIDS, OF AN ALREADY EXISTING MEDICINAL PRODUCT FROM A DENIMOUS MOLECULE OF CONTRAINDICATIONS AND ADVERSE REACTIONS.
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
AU3222893A (en) * 1991-11-25 1993-06-28 University Of Michigan, The Therapeutic composition and method for preventing reperfusion injury
JP3073309B2 (en) * 1992-03-27 2000-08-07 雪印乳業株式会社 Sialic acid-bound 5-deazaflavin compounds

Also Published As

Publication number Publication date
AP620A (en) 1997-10-14
UY23844A1 (en) 1995-03-28
JPH09505804A (en) 1997-06-10
GB9421099D0 (en) 1994-12-07
EE9600057A (en) 1996-10-15
IL111338A0 (en) 1994-12-29
WO1995011028A1 (en) 1995-04-27
EP0739208A1 (en) 1996-10-30
GB9321558D0 (en) 1993-12-08
MD960168A (en) 1998-04-30
OA10579A (en) 2002-06-19
HRP940688A2 (en) 1997-04-30
NO961547L (en) 1996-06-19
PL314008A1 (en) 1996-08-05
CZ113796A3 (en) 1996-11-13
JO1866B1 (en) 1995-12-27
CO4520283A1 (en) 1997-10-15
CA2174552A1 (en) 1995-04-27
HUT76322A (en) 1997-08-28
GB2283913A (en) 1995-05-24
PE5596A1 (en) 1996-04-18
HU9601006D0 (en) 1996-06-28
SK50696A3 (en) 1997-01-08
ZA948191B (en) 1995-06-08
BR9407862A (en) 1997-05-20
BG100599A (en) 1997-02-28
MA23356A1 (en) 1995-07-01
CA2123825A1 (en) 1995-04-20
NO961547D0 (en) 1996-04-18
AU7943794A (en) 1995-05-08
CN1140992A (en) 1997-01-22

Similar Documents

Publication Publication Date Title
DE69400639D1 (en) Rehydratationsgetraenk
DE69426415D1 (en) Intrapulmonares hormonabgabesystem
DE69421914D1 (en) Ekg-sensor
DE69401926D1 (en) Hydroxamsäurederivate
DE69406448D1 (en) Luftreinigungsgerät
EP0699071A4 (en) Anti-viral guanosine-rich oligonucleotides
ZA947119B (en) Androstenones
DE69405713D1 (en) Carbonylierungsverfahren
DE69412242D1 (en) Orthopädisches gussmaterial
ZA948191B (en) Anti-viral agents
DE59407177D1 (en) 2-fluorcycloyhexen-derivate
DE69423875D1 (en) Hydrodealkylierungsverfahren
GB9414754D0 (en) Anti-viral agent
DE59409705D1 (en) 3-methoxy-2-phenyl-acrylsäuremethylester
GB9322576D0 (en) Antihaemostatic agents
DE69408437D1 (en) Oxychlorierungsverfahren
DE59408644D1 (en) Jacquardmaschine
DE69407946D1 (en) Oxychlorierungskatalysator
DE59408733D1 (en) Metallhalogenidentladungslampe
DE59410065D1 (en) 3-methoxy-2-phenyl-acrylsäuremethylester
GB9212276D0 (en) Anti-viral agents
DE69425743D1 (en) Faserreaktive anthrachinon-farbstoffe
DE69422299D1 (en) Photographisches reproduktionsgerät
DE69410761D1 (en) Polyacetalharzzusammensetzung
DE69412128D1 (en) Kühlcontainer